RNA-Seq – News and Features

News
UCB Selects Genedata to Manage Drug Target Information
UCB researchers in the UK and Belgium use the Genedata Phylosopher® combined with Expressionist® platform to support their drug discovery efforts.

News
bioMérieux and NuGEN Technologies Announce Cross-License and Supply Agreement
bioMérieux gets non-exclusive rights to NuGEN amplification technologies while NuGEN gains access to bioMérieux linear amplification technologies.

News
Expression Analysis is First Provider of NuGEN Technologies’ Solution for FFPE Specimens
Amplification and labeling system enables whole transcriptome expression profiling from small and degraded FFPE samples for Expression Analysis customers.

News
GATC Biotech will use Genome Sequencer Technology from Roche
GATC plans to use the Genome Sequencer to offer its customers all the applications within this technology, with a special focus on in-depth analysis of whole transcriptomes.

News
Compendia Bioscience and Ingenuity Partner to Integrate Cancer Gene Signature Data with Network Analysis Tools
The integrated products will allow users to navigate directly from cancer gene signatures discovered in Oncomine Professional to the pathway information from IPA.

News
Genedata Expands Collaboration with HepatoSys
Swiss-based computational biology provider Genedata AG announced a three-year expansion of their collaboration with the HepatoSys research network.

News
Sigma-Aldrich Signs Exclusive Agreement with Rubicon Genomics to Commercialize Transplex™
Rubicon Genomics will develop the TransPlex™ WTA technology which can be used for amplifying total RNA from a variety of sample sources.

News
Three Cancer Genome Characterization Centers Select Agilent’s Microarray Platform to Profile Cancers
All three institutions will rely on Agilent’s genomics solution, comprising microarrays, reagents, hardware and data analysis tools.

News
Cenix, Applied Biosystems and Dresden University Announce Collaboration
Collaboration to create facility for proteomics profiling of RNAi and drug effects in human cells.

News
Compugen Discloses Status of In Silico Discovered Therapeutic Candidates
Molecules targeted at various cancers, inflammatory diseases and cardio-vascular indications.
Advertisement